Research Topics
Genomes and Genes | John V HeymachSummaryAffiliation: The University of Texas Country: USA Publications
| Collaborators
|
Detail Information
Publications
Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancerJohn V Heymach
Department of Thoracic Head and Neck Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
Clin Cancer Res 12:4441s-4445s. 2006....
Effect of low-fat diets on plasma levels of NF-κB-regulated inflammatory cytokines and angiogenic factors in men with prostate cancerJohn V Heymach
Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
Cancer Prev Res (Phila) 4:1590-8. 2011..These results suggest that a LF diet without flaxseed may reduce levels of specific inflammatory CAFs and suggests that the NF-κB pathway may be a mediator of these changes...
The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignanciesPetros Nikolinakos
Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
J Thorac Oncol 3:S131-4. 2008..These trials will determine whether cediranib will join the growing armamentarium of therapeutic options for thoracic malignancies and broaden the number of patients with NSCLC who could potentially benefit from antiangiogenic therapy...- Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasionPierre Saintigny
Department of 1Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center 5The University of Texas Graduate School of Biomedical Sciences, Houston, TX 77030, USA
Mol Cancer Ther 11:2021-32. 2012..EphA4 gene expression is associated with an improved outcome in patients with resected lung adenocarcinoma, possibly by affecting cancer cell migration and invasion... - Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancerEmer O Hanrahan
University of Texas M D, Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 28:193-201. 2010..It is unknown whether chemotherapy or VEGFR inhibitor/chemotherapy combinations induce changes in these or other cytokines and angiogenic factors (CAFs) and whether such changes could be markers of benefit... - Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trialsHai T Tran
Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Lancet Oncol 13:827-37. 2012..We aimed to assess the prognostic and predictive associations of pretreatment plasma concentrations of cytokine and angiogenic factors (CAFs) with data from a phase 2 and a phase 3 trial of pazopanib treatment... - A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acidPeter E Zage
Division of Pediatrics, Children s Cancer Hospital, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 116:2465-75. 2010..The authors hypothesized that vandetanib combined with 13-cis-retinoic acid (CRA), a differentiating agent used in most current neuroblastoma treatment regimens, would be effective against neuroblastoma tumor models... - Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancerEmer O Hanrahan
The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Clin Cancer Res 15:3600-9. 2009..In study 7, vandetanib monotherapy was inferior to carboplatin-paclitaxel. We performed an exploratory retrospective analysis of the relationship between baseline circulating VEGF concentrations and PFS... - CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinomaPierre Saintigny
Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Cancer Res 73:571-82. 2013..Expression of CXCL5 was regulated by promoter methylation. The CXCR2 axis may be an important target in smoking-related lung adenocarcinoma... - Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanibPetros G Nikolinakos
Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Res 70:2171-9. 2010..These data suggest that CAF profiling may be useful for identifying patients likely to benefit from pazopanib, and merit further investigation in clinical trials... - Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancerLauren Averett Byers
Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Mol Cancer Ther 9:1755-63. 2010..In conclusion, serum CAF profiling, particularly in HPV-negative patients, may be useful for identifying those at highest risk for recurrence... - Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1Lauren Averett Byers
Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Discov 2:798-811. 2012..On the basis of these results, clinical studies evaluating PARP and EZH2 inhibition, together with chemotherapy or other agents, warrant further investigation... - An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistanceLauren Averett Byers
Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Clin Cancer Res 19:279-90. 2013.... - Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trialRoy S Herbst
Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 432, Houston, TX 77030 4009, USA
Lancet Oncol 11:619-26. 2010..These results supported investigation of the combination in this larger, definitive phase 3 trial (ZODIAC)... - Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinomaTina Cascone
Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
J Clin Invest 121:1313-28. 2011..Understanding stromal signaling may be critical for developing biomarkers for angiogenesis inhibitors and improving combination regimens... - Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancerEmer O Hanrahan
Departments of Thoracic Head and Neck Medical Oncology and Cancer Biology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
Clin Cancer Res 13:s4617-22. 2007.... - Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancerLauren A Byers
Department of Cancer Biology, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
Clin Lung Cancer 8:S79-85. 2007..Phase III clinical trials are currently in progress to determine whether dual VEGF/EGFR inhibition, alone or in combination with chemotherapy, should become a standard therapeutic option for patients with NSCLC... - Angiogenesis inhibitors for lung cancer: clinical developments and future directionsGeorge Blumenschein
Department of Thoracic/Head and Neck Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA
J Thorac Oncol 1:744-8. 2006 - Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancerAparna A Kamat
Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Cancer Res 67:281-8. 2007..05) and led to a decrease in cell-free DNA levels (P < 0.05). Our results suggest that metronomic taxane chemotherapy with dual EGFR and VEGFR inhibition is highly efficacious and should be considered for future clinical trials... - DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapyBenjamin J Moeller
Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Clin Cancer Res 17:2035-43. 2011..We examined whether differential expression of double-strand DNA break (DSB) repair proteins in HNSCC, the chief mediators of DNA repair following irradiation, predict for treatment outcomes... - Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosisJosé Luis López Guerra
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Int J Radiat Oncol Biol Phys 84:e61-7. 2012..We investigated prognostic factors associated with survival in patients with non-small cell lung cancer (NSCLC) and oligometastatic disease at diagnosis, particularly the influence of local treatment to the primary site on prognosis... - Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2Xiao Feng Le
Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Cell Cycle 7:3747-58. 2008..Similar mechanisms may contribute to the clinical anti-tumor activity of trastuzumab in combination with inhibitors of VEGF signaling pathway in women with breast cancers which overexpress HER2... - Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with afliberceptJohn F de Groot
Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 17:4872-81. 2011..We investigated potential blood-based markers associated with radiographic changes to aflibercept, which binds VEGF and placental growth factor (PlGF) in patients with recurrent glioblastoma... - Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapyFei Yang
Departments of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Res 71:5512-21. 2011.... - C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expressionVikas Bhardwaj
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
J Thorac Oncol 7:1211-7. 2012..We hypothesized that inhibiting c-Met would increase the sensitivity of NSCLC cells to radiation, enhancing the therapeutic ratio, which may potentially translate into improved local control... - Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlookJoaquín Mateo
Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Mol Diagn Ther 16:151-61. 2012..These candidate markers should be considered in the development of future combination or sequential therapies... - The BATTLE trial: personalizing therapy for lung cancerEdward S Kim
Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Cancer Discov 1:44-53. 2011.... - Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancerLauren Averett Byers
Division of Cancer Medicine and Department of Thoracic Head and Neck Medical Oncology, Unit 432, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
Clin Cancer Res 15:6852-61. 2009..Activation of STAT3 by cellular Src (c-Src) promotes tumor progression. We hypothesized that c-Src inhibition could activate STAT3 by inducing a homeostatic feedback loop, contributing to c-Src inhibitor resistance... - Molecular targets for cancer chemopreventionWilliam N William
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
Nat Rev Drug Discov 8:213-25. 2009..Nevertheless, the broad translation of chemoprevention to the clinic is not yet a reality. Continuing research of molecular targets promises to expand the reach of chemoprevention and to personalize it as well... - The convergent development of molecular-targeted drugs for cancer treatment and preventionScott M Lippman
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
Clin Cancer Res 13:4035-41. 2007..These several advances are creating a convergence of cancer therapy with cancer prevention that promises to streamline the development of targeted drugs and improve the control of major cancers... - Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistanceScott Kopetz
University of Texas MD Anderson Cancer Center Lyndon B Johnson Hospital, Harris County Hospital District, Houston, TX, USA
J Clin Oncol 28:453-9. 2010.... - Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotypeYuji Piao
Brain Tumor Center, Department of Neuro Oncology, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Neuro Oncol 14:1379-92. 2012..Collectively, our results demonstrate a more prolonged decrease in tumor vascularity with bevacizumab than with sunitinib, associated with a delay in the development of hypoxia and sustained reduction of infiltrated myeloid cells... - Circulating biomarkers in advanced renal cell carcinoma: clinical applicationsMaria Hernandez-Yanez
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
Curr Oncol Rep 14:221-9. 2012..This review summarizes recent developments in identifying circulating biomarkers of targeted therapies for metastatic RCC, including soluble proteins and circulating cells... - Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancerShervin M Shirvani
Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 82:e91-7. 2012.... - Vascular endothelial growth factor (VEGF) pathwayMonique Nilsson
Department of Cancer Biology, University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030-4009, USA
J Thorac Oncol 1:768-70. 2006 - Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancerRobert L Coleman
Department of Gynecologic Oncology and Reproductive Medicine, M D Anderson Cancer Center, Houston, TX 77030, USA
Lancet Oncol 12:1109-17. 2011..We assessed the safety, tolerance, pharmacokinetics, relevant circulating and image-derived biomarkers, and clinical activity of combination aflibercept and docetaxel in this population... - Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinomaAmado J Zurita
Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1374, Houston, TX 77030 4009, USA
Cancer 115:2346-54. 2009..Further preclinical and translational validation studies are still needed to determine their practical utility in the clinical setting... - Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesisRoy S Herbst
The University of Texas MD Anderson Cancer Center, Department of Thoracic Head and Neck Medical Oncology, 1515 Holcombe Boulevard, Unit 432, Houston, TX 77030 4009, USA
Expert Opin Investig Drugs 16:239-49. 2007..Clinical development is also ongoing in other tumor types and encouraging evidence of antitumor activity has been reported in patients with metastatic hereditary medullary thyroid cancer... - Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention ResearchAshraful Hoque
Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
Cancer Res 67:8989-93. 2007.... - Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cellsXiaoying Liu
Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Biochem Pharmacol 83:1456-64. 2012..Our results indicate that NSC-743380 is a potent anticancer agent for lung cancer and that its apoptotic effects in lung cancer cells are mediated by induction of ROS through STAT3 inhibition... - miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1Jonathon D Roybal
University of Texas MD Anderson Cancer Center, Box 432, 1515 Holcombe Blvd, Houston, TX 77030, USA
Mol Cancer Res 9:25-35. 2011..Flt1 knockdown decreased the growth and metastasis of tumor cells in syngeneic mice. We conclude that miR-200 suppresses lung tumorigenesis by targeting Flt1... - Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668Darren W Davis
Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Clin Cancer Res 11:678-89. 2005..CONCLUSIONS: SU5416 and SU6668 displayed biological activity in xenografts. However, neither drug produced marked biological activity in primary patient tumors... - Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancerJames W Welsh
Department of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
J Clin Oncol 31:895-902. 2013..Additional end points were radiologic response and safety... - Blasted cell line namesJing Wang
Department of Bioinformatics and Computational Biology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
Cancer Inform 9:251-5. 2010..Most of the variations appeared to involve punctuation, white space, or their absence, at the juncture between alphabetic and numeric portions of the cell line name... - Inhibition of intra-abdominal adhesion formation with the angiogenesis inhibitor sunitinibSendia Kim
Department of Surgery, Children s Hospital Boston Harvard Medical School, Boston, Massachusetts 02115, USA
J Surg Res 149:115-9. 2008..To determine the effects of sunitinib, a vascular endothelial growth factor receptor 2 (VEGFR-2) antagonist, on intra-abdominal adhesions... - Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activityPaul Beaudry
Children's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
Clin Cancer Res 11:3514-22. 2005..Therefore, assessing both mature CECs and CEPs may provide insights into the mechanism of antiangiogenic agents and serve as an early surrogate marker of biological activity... - Emerging antiangiogenic agents in lung cancerDavid Lee
CIG Media Group, LP, Dallas, TX, USA
Clin Lung Cancer 7:304-8. 2006..Data from phase I/II trials have indicated the clinical feasibility of these agents, which are currently being investigated in phase II/III trials... - Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agentsThomas J Lynch
Division of Hematology/Oncology, Massachusetts General Hospital, Boston 02114, and University of Colorado Cancer Center, Aurora, USA
Clin Cancer Res 12:4365s-4371s. 2006 - Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumorsMatthew H Kulke
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 24:3555-61. 2006..We therefore performed a multicenter phase II study of rhEndostatin in patients with carcinoid or pancreatic neuroendocrine tumors... - Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancerJeffrey A Engelman
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
J Clin Invest 116:2695-706. 2006.... - Lung cancerRoy S Herbst
Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA
N Engl J Med 359:1367-80. 2008 - Second-line treatment of advanced non-small cell lung cancerCesare Gridelli
Medical Oncology, S G Moscati Hospital, Avellino, Italy
J Thorac Oncol 3:430-40. 2008..Further research is mandatory, to find better treatments, and to identify clinical and molecular predictive markers of efficacy, both for chemotherapy and for novel biologic agents... - Farnesyl transferase inhibitors for patients with lung cancerBruce E Johnson
Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
Clin Cancer Res 10:4254s-4257s. 2004..R115777 and L-778,123 were well tolerated in these studies but showed no significant activity as single-agent therapy in relapsed SCLC or untreated NSLC... - Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cellsTina Cascone
Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery F Magrassi and A Lanzara, Second University of Naples, Naples, Italy
J Cell Physiol 216:698-707. 2008.... - Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancerJohn V Heymach
Dana Farber Cancer Institute, Boston, MA, USA
J Clin Oncol 25:4270-7. 2007..The activity of vandetanib plus docetaxel was assessed in patients with previously treated non-small-cell lung cancer (NSCLC)... - Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapyThomas J Lynch
Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
J Thorac Oncol 3:S107-12. 2008..A CME activity based on this summary is also available at www.informedicalcme.com/cme... - PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinibJeffrey A Engelman
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
Cancer Res 67:11924-32. 2007..These preclinical evaluations support further clinical development of PF00299804 for cancers with mutations and/or amplifications of ERBB family members... - Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomasJohn V Heymach
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
Clin Cancer Res 10:5732-40. 2004..Correlative studies suggest that VEGF receptor or KIT inhibition was incomplete in at least some cases, providing a possible explanation for the observed lack of activity... - Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cellsDhara N Amin
Vascular Biology Program, Children s Hospital and Harvard Medical School, Boston, MA 02115, USA
Microvasc Res 76:15-22. 2008..Our data provide a molecular rationale for combination therapies targeting both EGF and VEGF signaling on the tumor vasculature... - Therapeutic efficacy of endostatin exhibits a biphasic dose-response curveIlhan Celik
Institute of Theoretical Surgery, University Hospital Marburg, Philipps University, Baldingerstrasse, Marburg, Germany
Cancer Res 65:11044-50. 2005..When these results are taken together with two previous reports of angiogenesis inhibitors with a U-shaped dose-response, they suggest that other regulators of endothelial growth may display a similar pattern... - Novel agents in the treatment of lung cancer: Fourth Cambridge ConferenceThomas J Lynch
Division of Hematology Oncology, Massachusetts General Hospital, 55 Fruit Street, Yawkey, 7th Floor, Suite 7601, Boston, MA 02114, USA
Clin Cancer Res 13:s4583-8. 2007.... - Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumorAnat Norden Zfoni
Children s Hospital Boston, Boston, Massachusetts, USA
Clin Cancer Res 13:2643-50. 2007..In this study, we investigated potential blood-based biomarkers for SU11248 (sunitinib malate), a multitargeted tyrosine kinase inhibitor, in patients with metastatic imatinib-refractory gastrointestinal stromal tumors...